ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
From Clinical Care Options (CCO) and Anli Liu, MD, expert insight on new epilepsy data from AAN 2021: MONEAD pregnancy, cenobamate, cannabidiol, soticlestat
Anli A. Liu, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Released: May 28, 2021
Expired:
May 27, 2022
From Clinical Care Options (CCO), new data from AAN 2021 on cenobamate, lamotrigine, carbamazepine for uncontrolled focal seizures from the C021 study
From Clinical Care Options (CCO), new data from AAN 2021 on CBD add-on therapy in treatment-resistant epilepsy
Expert commentary from CCO on key clinical information about each FDA-approved agent for treating spinal muscular atrophy (SMA)
Nancy L. Kuntz, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Nurse Practitioners:
0.25 NAPNAP CE contact hours
Released: October 23, 2020
Expired:
No longer available for credit
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Contact NAPNAP
For customer support please email: ce@napnap.org
Mailing Address
5 Hanover Square
Suite 1401
New York, NY 10004
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
